Waldenström's Macroglobulinemia

ISBN-13: 9783319225838 / Angielski / Twarda / 2016 / 377 str.

Veronique Leblond; Steve Treon; Meletios Dimoploulos

Opis

This book sheds new light on clinical, biological and therapeutic data on the rare disease Waldenstrom's Macroglobulinemia (WM) with the participation of widely-recognized experts, involved in this field. It represents the efforts of physicians, scientists and patients, all around the world, to better understand and cure this rare disease.Considerable advances in the diagnosis, treatment indications, response criteria, prognostic factors and treatment options have been made since Dr Jan Waldenstrom first reported this "new syndrome" 70 years ago. Particularly instrumental in advancing of our understanding of WM have been the eight international workshops devoted to this disease. New, exciting molecular data have recently been reported, allowing us to revisit the oncogenic events leading to WM B-cell proliferation and to use newly available compounds targeting oncogenic pathways.

Widoczna okładka, to zdjęcie poglądowe, a rzeczywista szata graficzna może różnić się od prezentowanej. Nie gwarantujemy zgodności okładki z prezentowanym zdjęciem.

Spis treści

Preface: Tribute to J Waldenström

Part I: Tumor Cells and microenvironment

1. Waldenström Macroglobulinaemia: Pathological Features and Diagnostic Assessment

2. Waldenström’s Macroglobulinemia Immunophenotype

3. Predispositions and Origins of Waldenstrom Macroglobulinemia: Implications from Genetic Analysis

4. Cytogenetics in Waldenström Macroglobulinemia (WM)

5. Genetic and Signaling Abnormalities in Waldenström’s Macroglobulinemia

6. Molecular Pathways in Growth and Survival: Epigenomics

7. The Bone Marrow Microenvironment and Tumor Cells Interactions in Waldenström’s Macroglobulinemia

8. Waldenström’s Macroglobulinaemia: Immunosurveillance and the Immune Micro-environment

Part II: Epidemiology and Genetic Predisposition

9. Epidemiology of Waldenström Macroglobulinemia

10. Genetic Predisposition to Waldenström Macroglobulinemia

11. Immunoglobulin Type M Monoclonal Gammopathy of Undetermined Significance (IgM-MGUS)

Part III Clinical Features

12. Hyperviscosity Syndrome, Cold Agglutinin Hemolytic Anemia, and Cryoglobulinemia

13. Neuropathy in Waldenström’s Macroglobulinaemia

14. IgM Amyloidosis

15. The Bing-Neel Syndrome

16. Unusual Manifestations of IgM Monoclonal Gammopathies

Part IV: Laboratory Investigations

17. Laboratory Investigations and Findings: Hematological Abnormalities, Biochemical Investigations, Free Light and Heavy Chains

Part V: Response

18. Response Assessment in Waldenström’s Macroglobulinaemia

Part VI: Prognostic Factors

19. Risk Stratification in Waldenström Macroglobulinemia

Part VII: Treatment Options and Recommendations

20. Indications for Treatment of Waldenström’s Macroglobulinemia

21. Immunotherapy in Waldenström’s Macroglobulinemia

22. Immunomodulatory Agents and Proteasome Inhibitors in Waldenström’s Macroglobulinemia

23. Signal Inhibitors in Waldenström’s Macroglobulinemia

24. High-Dose Therapy and Haemopoietic Stem Cell Transplantation in Waldenström’s Macroglobulinaemia

25. Long-Term Toxicity of Therapy in Waldenström Macroglobulinemia

26. Treatment Recommendations in Waldenström Macroglobulinemia

O autorze

Véronique Leblond, Professor in Hematology, is the head of the department of Hematology at Pitié Salpêtrière Hospital, Paris, France. She is the chair of the “French Cooperative Group on Chronic Lymphocytic Leukemia and Waldenström’s Macroglobulinemia: FCG CLL-WM” including more than 90 centers in France and Belgium. She is responsible for a rare tumor network (K-VIROGREF) dedicated to the management of transplant recipients with virus-induced tumors and funded by the French national Institute for cancer in 2012. The team historically focuses on chronic B-cell lymphoproliferative disorders, amyloidosis, on ocular and CNS lymphoma and on lymphoproliferations in immunosuppressed patients (HIV, organ-transplanted patients). She is the head of GRECHY, affiliated to the PhD school ED394 “Physiology & Physio-pathology”. Steven Treon is the Director of the Bing Center for Waldenström’s Research and an attending physician for medical oncology, at Dana-Farber Cancer Institute and Brigham and Women’s Hospital, in Boston, Massachusetts. He is also an Associate Professor of Medicine at Harvard Medical School in Boston, and is the Chair of the Waldenström's Macroglobulinemia Clinical Trials Group. Dr Treon’s main research interests focus on understanding the genetic basis and pathogenesis of Waldenström’s macroglobulinemia and the development of therapeutics for this malignancy. Meletios A. Dimopoulos, MD is Professor and Chairman of the Department of Clinical Therapeutics at the University Athens School of Medicine, Athens, Greece. He is a member of numerous scientific societies and has authored more than 650 publications (April 2013) in peer-reviewed journals. Dr. Dimopoulos serves on the Scientific Advisory Boards of the Multiple Myeloma Research Foundation, of the International Myeloma Foundation, of the International Waldenstrom’s Macroglobulinemia Foundation and he is a member of the Board of the European Myeloma Network.

Blurb

This book sheds new light on clinical, biological and therapeutic data on the rare disease Waldenström’s Macroglobulinemia (WM) with the participation of widely-recognized experts, involved in this field. It represents the efforts of physicians, scientists and patients, all around the world, to better understand and cure this rare disease.

Considerable advances in the diagnosis, treatment indications, response criteria, prognostic factors and treatment options have been made since Dr Jan Waldenström first reported this “new syndrome“ 70 years ago. Particularly instrumental in advancing of our understanding of WM have been the eight  international workshops devoted to this disease. New, exciting molecular data have recently been reported, allowing us to revisit the oncogenic events leading to WM B-cell proliferation and to use newly available compounds targeting oncogenic pathways.